This report was prepared n an aocou.it of work sponsored by rh* United States Government. Ne-ri'*.-he United States nor the Energy Research and Dcvdopmtn-Admmistration. nor any of ffi*-r employees, nor any o* their contractors, subcontractors, or their employees, makes any warranty, express or implied,-x assumes any legal liability or responsibi'ity for the accuracy, completeness or usefulness of any information, apparatus, product or process disclosed, or represents that its use would not infringe pr-vatdy owned rights. OR NL 4866 UC 76-Molon S*lt Reactor Ttchnology Co-"*.

No abstract

No abstract

NOTICE This document contains information of a preliminary nature. It is subject to revision or correction and therefore does not represent a final report.

Vol. 63 systems, with respect to the causes of this selectivity and to the nature and spacing of the supported modifying agent, should help to develop a better understanding of the actual forces involved. Solubilities of He, Ne and A were measured a t pressures from 1 to 2 atmospheres in a mixture of LiF, NaF and K F (46.5-11.542.0 mole %) a t 600, 700 and 800'. The solubilities increase linearly with gas pressure, decrease with increasing atomic weight (radius) of the solute and increase with increasing temperature. Henry's law constants in moles of solute/ (cm.3 of solution)(atmosphere) at 600' are 11.3 =k 0.7 X 10-8, 4.36 f 0.20 x 10-8 and 0.90 =k 0.04 X 10-8 and the enthalpies of solution are 8.0, 8.9 and 12.4 kcal./mole for He, Ne and A, res ectively. A model which equates the free energy of solution of the gas to the free energy of formation of holes the size orthe gas molecules in a continuous fluid having the same surface tension as the solvent yields solubility values which are in good agreement with those observed.

No abstract

No abstract

Systemic toxicity is an undesired consequence of the majority of chemotherapeutic drugs. Multifunctional nanoparticles with combined diagnostic and therapeutic functions show great promise towards personalized nanomedicine. Halloysite clay nanotubes (HNTs) have shown potential as a drug delivery vehicle, and its surface can be modified and tailored as a targeted drug delivery system. In this short report, we modified the HNT surface by covalently bonding folic acid (FA) and fluorescein isothiocyanate (FITC). The modification of HNTs with folic acid imparts the potential to target tumor cells selectively. The addition of FITC offers a method for quantifying the effectiveness of the FA tagged HNTs ability to target tumor cells. We documented cell uptake of our bi-functionalized HNT (bHNT) through phase contrast and epi-fluorescent microscopy. bHNTs showed no signs of cytotoxicity up to a concentration of 150 µg/mL. The increase in cell death with increased bHNT concentration may be due to induced cytotoxicity resulting from intracellular bHNT accumulation that disrupts cellular function leading to cell death. With HNTs recognized as having the ability to serve as both a nanocontainer and nanocarrier, we envision our construct as a potential modular platform for potential use in cancer therapeutics. The HNT interior can be loaded with a variety of anti-cancer drugs (or other chemotherapeutics) and serve as a "death cargo" designed to kill cancer cells while providing feedback imaging data on drug efficacy. The surface of the HNT can be modified with gold or silver nanoparticles and used in photothermal therapy by converting light to heat inside tumors. Our HNT-based drug delivery system has the potential to provide localized and targeted therapies that limit or reduce side effects, reduce patient costs and length of hospital stays, and improve quality of life. However, further research is needed to validate the potential of this new chemotherapeutic drug delivery system.